Elacestrant-d10

• Description :

  Elacestrant-d10 is the deuterium labeled of Elacestrant (HY-19822) . Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also inhibits growth of ER+ breast cancer cell lines in vitro and in vivo[1][2].

• Product Name Alternative :

  RAD1901-d10

• UNSPSC :

  12352005

• Target :

  Estrogen Receptor/ERR; Isotope-Labeled Compounds

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Others; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Solubility :

  10 mM in DMSO

• Smiles :

  OC1=C(C([2H])=C2C[C@@H](CCC2=C1[2H])C3=C(C([2H])=C(C([2H])=C3N(CC4=C(C([2H])=C(C([2H])=C4[2H])CCNCC)[2H])CC)OC)[2H])[2H]

• Molecular Formula :

  C30H28D10N2O2

• Molecular Weight :

  468.70

• References & Citations :

  [1]Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26 (9) :948-56.|[2]Bihani T, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models. Clin Cancer Res. 2017 Aug 15;23 (16) :4793-4804.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported